AstraZeneca (AZN)
Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity
Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity
📈 **POSITIVE** • Low confidence analysis (43%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (78%) **Content type:** General